Aravind Ramakrishnan1, H Joachim Deeg. 1. University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA.
Abstract
BACKGROUND: The marrow microenvironment is composed of a complex network of cells and extra cellular matrix that cooperate to regulate normal hematopoiesis. There is growing evidence that microenvironmental defects can contribute to the pathogenesis of hematological malignancies. OBJECTIVE/ METHODS: We review the role of the microenvironment in inducing and sustaining hematological malignancies. RESULTS/ CONCLUSIONS: Two basic mechanisms could explain the role of microenvironmental defects in the evolution of hematopoietic neoplasms. There is significant data to support the first mechanism, in which the malignant hematopoietic clone induces reversible functional changes in the microenvironment that result in improved growth conditions for the malignant cells. More recent studies from mouse models have indicated that a second mechanism involving primary microenvironmental defects can also result in malignancy.
BACKGROUND: The marrow microenvironment is composed of a complex network of cells and extra cellular matrix that cooperate to regulate normal hematopoiesis. There is growing evidence that microenvironmental defects can contribute to the pathogenesis of hematological malignancies. OBJECTIVE/ METHODS: We review the role of the microenvironment in inducing and sustaining hematological malignancies. RESULTS/ CONCLUSIONS: Two basic mechanisms could explain the role of microenvironmental defects in the evolution of hematopoietic neoplasms. There is significant data to support the first mechanism, in which the malignant hematopoietic clone induces reversible functional changes in the microenvironment that result in improved growth conditions for the malignant cells. More recent studies from mouse models have indicated that a second mechanism involving primary microenvironmental defects can also result in malignancy.
Authors: Alessandro Maria Vannucchi; Lucia Bianchi; Cristina Cellai; Francesco Paoletti; Rosa Alba Rana; Rodolfo Lorenzini; Giovanni Migliaccio; Anna Rita Migliaccio Journal: Blood Date: 2002-08-15 Impact factor: 22.113
Authors: Ana I Benito; Eileen Bryant; Michael R Loken; George E Sale; Richard A Nash; M John Gass; H Joachim Deeg Journal: Leuk Res Date: 2003-05 Impact factor: 3.156
Authors: Eugenia Flores-Figueroa; Guillermo Gutiérrez-Espíndola; Juan José Montesinos; Rosa María Arana-Trejo; Hector Mayani Journal: Leuk Res Date: 2002-07 Impact factor: 3.156
Authors: Constantine S Mitsiades; Nicholas Mitsiades; Vassiliki Poulaki; Robert Schlossman; Masaharu Akiyama; Dharminder Chauhan; Teru Hideshima; Steven P Treon; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson Journal: Oncogene Date: 2002-08-22 Impact factor: 9.867
Authors: Beate Heissig; Koichi Hattori; Sergio Dias; Matthias Friedrich; Barbara Ferris; Neil R Hackett; Ronald G Crystal; Peter Besmer; David Lyden; Malcolm A S Moore; Zena Werb; Shahin Rafii Journal: Cell Date: 2002-05-31 Impact factor: 41.582
Authors: Ingmar Bruns; Ron-Patrick Cadeddu; Ines Brueckmann; Julia Fröbel; Stefanie Geyh; Sebastian Büst; Johannes C Fischer; Frederik Roels; Christian Matthias Wilk; Frank A Schildberg; Ali-Nuri Hünerlitürkoglu; Christoph Zilkens; Marcus Jäger; Ulrich Steidl; Fabian Zohren; Roland Fenk; Guido Kobbe; Benedict Brors; Akos Czibere; Thomas Schroeder; Andreas Trumpp; Rainer Haas Journal: Blood Date: 2012-04-18 Impact factor: 22.113
Authors: Tomás Alvaro; Luis de la Cruz-Merino; Fernando Henao-Carrasco; José Luis Villar Rodríguez; David Vicente Baz; Manuel Codes Manuel de Villena; Mariano Provencio Journal: J Biomed Biotechnol Date: 2010-08-12
Authors: Yao Liu; Xing-hua Chen; Ying-jian Si; Zhong-jun Li; Lei Gao; Li Gao; Cheng Zhang; Xi Zhang Journal: PLoS One Date: 2012-02-23 Impact factor: 3.240